Drug Lobby, Pricing Advocates At Odds Over USTR's Special 301 IP Report

April 27, 2018
The brand pharmaceutical lobby is pleased with a new report from the Office of the U.S. Trade Representative calling out countries with allegedly substandard intellectual property protections, but that report is leaving advocates for lower drug prices feeling indignant. Public Citizen sees the report, USTR's annual Special 301 Report on Intellectual Property Rights, as an extension of President Donald Trump's belief that lower drug prices in other countries lead to higher prices at home, while the Pharmaceutical Research and Manufacturers...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.